Glenmark Pharmaceuticals Inc., USA has strengthened its injectable medicine portfolio with the acquisition and immediate launch of Acetylcysteine Injection in the United States market. The company acquired the Abbreviated New Drug Application (ANDA) for the 6 gm/30 mL (200 mg/mL) Single-Dose Vials formulation from Aspen Pharma USA Inc.
Strategic Market Entry
The newly launched injection is therapeutically equivalent to Cumberland Pharmaceuticals' Acetadote Injection, a well-established product in the market. According to IQVIA data, the reference product achieved significant market presence with approximately $15.2 million in annual sales for the 12-month period ending January 2025.
Marc Kikuchi, President & Business Head of North America at Glenmark, emphasized the strategic importance of this acquisition, stating that it reinforces the company's injectable portfolio while aligning with their focused growth strategy in the hospital segment.
Company Profile and Global Presence
Glenmark Pharmaceuticals maintains a substantial global footprint with operations spanning more than 80 countries and 11 manufacturing facilities across four continents. The company has established itself as a significant player in the pharmaceutical industry, focusing on key therapeutic areas including respiratory, dermatology, and oncology across branded, generic, and over-the-counter segments.
The company's market position is notable, ranking among the top 100 biopharmaceutical companies by pharmaceutical sales according to Scrip 100, and securing a position in the top 50 generics and biosimilar companies by sales according to Generics Bulletin.
Environmental Commitment
In a demonstration of its commitment to sustainability, Glenmark achieved a significant environmental milestone in 2023. The company's Green House Gas emission reduction targets received approval from the Science Based Target initiative, making it only the second pharmaceutical company in India to achieve this distinction.
